openPR Logo
Press release

Non-alcoholic Steatohepatitis (NASH) Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeu

01-13-2025 02:33 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Non-alcoholic Steatohepatitis (NASH) Pipeline Insights

Non-alcoholic Steatohepatitis (NASH) Pipeline Insights

Non-alcoholic Steatohepatitis (NASH) Pipeline constitutes 80+ key companies continuously working towards developing 80+ Non-alcoholic Steatohepatitis (NASH) treatment therapies, analyzes DelveInsight.

Non-alcoholic Steatohepatitis (NASH) Overview:

Nonalcoholic steatohepatitis (NASH) is a liver condition characterized by inflammation and damage caused by fat buildup in the liver. It falls under the broader category of nonalcoholic fatty liver disease (NAFLD), which is divided into two types: isolated fatty liver, where only fat accumulates, and NASH, where fat buildup is accompanied by inflammation and liver cell damage. Over time, NASH can progress to liver fibrosis, cirrhosis, and liver cancer, with 30-40% of patients developing fibrosis. NASH is not a condition exclusive to NAFLD and can also be linked to other liver diseases, such as chronic hepatitis C.

NASH is typically categorized into primary NASH (linked to obesity and diabetes without excessive alcohol use) and secondary NASH (caused by toxins or drugs). Key risk factors include obesity, metabolic syndrome, insulin resistance, and type 2 diabetes, which are strongly associated with the disease. Other conditions such as PCOD, Wilson disease, and lipodystrophies are also linked to NASH.

The development of NASH follows the "two-hit" hypothesis: the first hit involves fat buildup in the liver (steatosis), and the second hit involves oxidative stress and liver cell injury. This leads to mitochondrial dysfunction, inflammation, and eventual liver damage, progressing to fibrosis and cirrhosis. Diagnosis is often incidental, detected through abnormal liver tests or imaging. While liver biopsy remains the gold standard for diagnosing NASH, it has limitations, and non-invasive tests like FibroScan and APRI are often used to assess liver damage.

Treatment for NASH primarily focuses on lifestyle changes, such as weight loss (5%-10%), exercise, and dietary adjustments, including reducing high fructose corn syrup and increasing omega-3 fatty acids. Medications like antioxidants (vitamin E) and thiazolidinediones may also help, but caution is needed with the latter. Bariatric surgery can be an option for severely obese patients, and liver transplantation is considered for those with advanced cirrhosis, though there is a risk of NASH recurrence.

Request for a detailed insights report on Non-alcoholic Steatohepatitis (NASH) pipeline insights @ https://www.delveinsight.com/report-store/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Non-alcoholic Steatohepatitis (NASH) Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Non-alcoholic Steatohepatitis (NASH) Therapeutics Market.

Key Takeaways from the Non-alcoholic Steatohepatitis (NASH) Pipeline Report

DelveInsight's Non-alcoholic Steatohepatitis (NASH) pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Non-alcoholic Steatohepatitis (NASH) treatment.
In November 2024, Novo Nordisk announced positive results for semaglutide in treating Nonalcoholic Steatohepatitis (NASH). The Phase 3 Essence trial showed that a once-weekly 2.4 mg dose of semaglutide significantly improved liver fibrosis and resolved steatohepatitis in NASH patients with stage 2 or 3 fibrosis, without worsening liver fibrosis, successfully meeting the primary endpoints.
In October 2024, Sagimet Biosciences (SGMT) revealed the successful conclusion of end-of-Phase 2 discussions with the FDA, allowing denifanstat to move forward into Phase 3 clinical trials for metabolic dysfunction-associated steatohepatitis.
In July 2024, Inventiva provided updates on its Phase III NATiV3 clinical program, assessing lanifibranor for treating metabolic dysfunction-associated steatohepatitis/non-alcoholic steatohepatitis (MASH/NASH). Recruitment for the trial is currently underway at 347 sites across 19 countries.
Key Non-alcoholic Steatohepatitis (NASH) companies such as Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics, and others are evaluating new drugs for Non-alcoholic Steatohepatitis (NASH) to improve the treatment landscape.
Promising Non-alcoholic Steatohepatitis (NASH) pipeline therapies in various stages of development include Lanifibranor, MSDC-0602K, TERN-501, HTD 1801, and others.

Non-alcoholic Steatohepatitis (NASH) Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Non-alcoholic Steatohepatitis (NASH) Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-alcoholic Steatohepatitis (NASH) treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Non-alcoholic Steatohepatitis (NASH) market.

Download our free sample page report on Non-alcoholic Steatohepatitis (NASH) pipeline insights @ https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Non-alcoholic Steatohepatitis (NASH) Emerging Drugs

Lanifibranor: Inventiva Pharma
MSDC-0602K: Cirius Therapeutics
TERN-501: Terns Pharmaceuticals
HTD 1801: HighTide Biopharma

Non-alcoholic Steatohepatitis (NASH) Companies

There are over 80 major companies working on therapies for Nonalcoholic Steatohepatitis. Among them, Cirius Therapeutics and Inventiva Pharma have drug candidates in the most advanced stage, specifically Phase III.

DelveInsight's report covers around 22+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Non-alcoholic Steatohepatitis (NASH) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Non-alcoholic Steatohepatitis (NASH) Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Non-alcoholic Steatohepatitis (NASH) Therapies and Key Companies: Non-alcoholic Steatohepatitis (NASH) Clinical Trials and advancements @ https://www.delveinsight.com/report-store/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Non-alcoholic Steatohepatitis (NASH) Pipeline Therapeutic Assessment
• Non-alcoholic Steatohepatitis (NASH) Assessment by Product Type
• Non-alcoholic Steatohepatitis (NASH) By Stage
• Non-alcoholic Steatohepatitis (NASH) Assessment by Route of Administration
• Non-alcoholic Steatohepatitis (NASH) Assessment by Molecule Type

Download Non-alcoholic Steatohepatitis (NASH) Sample report to know in detail about the Non-alcoholic Steatohepatitis (NASH) treatment market @ Non-alcoholic Steatohepatitis (NASH) Therapeutic Assessment @ https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Non-alcoholic Steatohepatitis (NASH) Current Treatment Patterns
4. Non-alcoholic Steatohepatitis (NASH) - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Non-alcoholic Steatohepatitis (NASH) Late-Stage Products (Phase-III)
7. Non-alcoholic Steatohepatitis (NASH) Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Non-alcoholic Steatohepatitis (NASH) Discontinued Products
13. Non-alcoholic Steatohepatitis (NASH) Product Profiles
14. Non-alcoholic Steatohepatitis (NASH) Key Companies
15. Non-alcoholic Steatohepatitis (NASH) Key Products
16. Dormant and Discontinued Products
17. Non-alcoholic Steatohepatitis (NASH) Unmet Needs
18. Non-alcoholic Steatohepatitis (NASH) Future Perspectives
19. Non-alcoholic Steatohepatitis (NASH) Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Non-alcoholic Steatohepatitis (NASH) Pipeline Reports Offerings: https://www.delveinsight.com/report-store/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Non-alcoholic Steatohepatitis (NASH) Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeu here

News-ID: 3812828 • Views:

More Releases from DelveInsight Business Research LLP

Cutaneous Lupus Erythematosus Treatment Market Size Report 2034 | Horizon Therapeutics, Gilead Sciences, Merck KGaA
Cutaneous Lupus Erythematosus Treatment Market Size Report 2034 | Horizon Therap …
DelveInsight's "Cutaneous Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Cutaneous Lupus Erythematosus, historical and forecasted epidemiology as well as the Cutaneous Lupus Erythematosus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Key Takeaways from the Cutaneous Lupus Erythematosus Market Research Report • The increase in Cutaneous Lupus Erythematosus Market Size is a direct consequence of the
Congestive Heart Failure Treatment Market Size Report 2032 | Novartis, Boehringer Ingelheim, Eli Lilly, Bayer, Merck, AstraZeneca, Amgen, Otsuka Pharmaceutical, Cytokinetics, Mesoblast, Novo Nordisk, Lexicon Pharmaceuticals, scPharmaceuticals
Congestive Heart Failure Treatment Market Size Report 2032 | Novartis, Boehringe …
DelveInsight's "Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of Congestive Heart Failure, historical and forecasted epidemiology as well as the Congestive Heart Failure market trends in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan. Key Takeaways from the Congestive Heart Failure Market Research Report • The increase in Congestive Heart Failure Market Size is a direct consequence
Chronic Spontaneous Urticaria Therapeutics Market Size Report 2032 | Novartis, Sanofi Pharmaceutical, Genentech, AstraZeneca, Kiniksa Pharmaceuticals, Ltd, United BioPharma, GlaxoSmithKline, Allakos, Eli Lilly and Company
Chronic Spontaneous Urticaria Therapeutics Market Size Report 2032 | Novartis, S …
DelveInsight's "Chronic Spontaneous Urticaria Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of chronic spontaneous Urticaria, historical and forecasted epidemiology, as well as the chronic spontaneous Urticaria market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. Key Takeaways from the Chronic Spontaneous Urticaria Market Research Report • The increase in Chronic Spontaneous Urticaria Market Size is a direct
Chronic Rhinosinusitis with Nasal Polyps Treatment Market Size Report 2032 | AstraZeneca, Amgen, GlaxoSmithKline, Keymed Biosciences, Biohaven Pharmaceuticals
Chronic Rhinosinusitis with Nasal Polyps Treatment Market Size Report 2032 | Ast …
DelveInsight's 'Chronic Rhinosinusitis with Nasal Polyps Market Insights, Epidemiology, and Market Forecast-2032' report deliver an in-depth understanding of the Chronic Rhinosinusitis with Nasal Polyps, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. Key Takeaways from the Chronic Rhinosinusitis with Nasal Polyps Market Report • The increase in Chronic Rhinosinusitis with Nasal Polyps Market Size is a

All 5 Releases


More Releases for NASH

NASH Market Insight and Landscape report
Report Snapshot: NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their
IQ4I Research published “Non-alcoholic steatohepataitis (NASH) Pipeline Analys …
“Non-alcoholic steatohepataitis (NASH) Pipeline Analysis” gives comprehensive insights on the various drugs being developed for the treatment of NASH. The report covers all the drugs that are in various phases of development (Discovery, Preclinical & Clinical). The pipeline focuses on novel pharmacologic drugs & regenerative medicines covering small molecules, antibodies, stem cell therapies, recombinant proteins and RNA-based therapeutics, but excludes symptom relief drugs, generic combinations and supplemental drugs. The report
Growing Prevalence of NASH to Increase Adoption of Therapeutics
"The Report OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" MarketResearchReports.biz has itemized the addition of a new market research report to its report repository. The research publication is titled, “Opportunity Analyzer: NASH - Opportunity Analysis and Forecasts to 2026.” The statistical surveying study is a watchful inspection of the general market
OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026
First described in 1980, nonalcoholic steatohepatitis (NASH) (ICD-10-CM = K75.81) is a condition that develops as a subgroup of nonalcoholic fatty liver disease (NAFLD) when excessive fat buildup is accompanied by liver cell injury and inflammation. NAFLD is defined by excessive fat accumulation in the form of triglycerides (steatosis) in the liver. Progression of this condition to NASH dramatically increases the risk of cirrhosis, liver failure, and hepatocellular carcinoma, and
04-07-2017 | Arts & Culture
Memphia PR
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Don’t Know. Recorded at the legendary RAK Studios, She Don’t Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Don’t Know’s leading single CK is an infectious number which is sure to be a hit for 2017. Listening to the Beatles and Jack White growing
Nash Technologies at GITEX/GULFCOMMS 2010
Harvey Nash subsidiary presents expert services to telecom operators in the Middle East, Africa and South Asia region Nürnberg/Germany, 10th September 2010 – For the first time Nash Technologies will be present at GITEX/GULFCOMMS, the largest international trade event for mobile, fixed, IP and satellite communications for the Middle East, Africa and South Asia region, in Dubai from 17th to 21st October 2010 offering its telecom expert services. Nash Technologies will